Business Wire

NJ-GARP

Share
GARP to Postpone May Exams Due to Uncertainty Surrounding COVID-19

The Global Association of Risk Professionals (GARP) has announced that it has postponed its global May exams for both The Financial Risk Manager® (FRM) and Energy Risk Professional® (ERP) certifications due to increased concerns and uncertainty about the COVID-19 virus.

“Given the global uncertainty around this pandemic, we must focus on the health and safety of exam participants and partners. As a result, we are postponing the May exam around the world,” said Richard Apostolik, CEO of GARP. “We are very saddened and disappointed that we are unable to hold the exams in May, but we know it’s the right decision based on the information we have today.”

GARP based its decision on guidelines from the World Health Organization and local health and education authorities, which have cited increased risk of potential spread of the COVID-19 virus in large or group gatherings. “After careful consultation among GARP’s management team and with our partners, we felt this was the only way to proceed during such an unprecedented global situation,” said Apostolik.

The FRM and ERP certifications are global certifications. GARP has postponed all exams, ensuring that it can deliver them as it typically does - at the same time all over the world.

All May FRM and ERP candidates will be automatically deferred to the new exam date later this year. GARP will provide regular updates on its website and via email and social media, ensuring candidates are kept as informed as possible.

“We will announce the new exam date as soon as it has been finalized with our global partners. As you can imagine, GARP is not the only global certification body dealing with this unprecedented situation. The uncertainty is affecting all of GARP’s global supply chain participants, and we’re working as quickly as possible to address this unfortunate situation,” said Apostolik.

“Our hearts and sincere thoughts go out to those who have been affected by the coronavirus. We continue to stay on top of the situation and are following guidance as it unfolds. We are committed to the needs of our candidates while also working in cooperation with all of our partners,” he added.

About the Global Association of Risk Professionals

The Global Association of Risk Professionals is a non-partisan, not-for-profit membership organization focused on elevating the practice of risk management. GARP offers role-based risk certification – the Financial Risk Manager® and Energy Risk Professional® – as well as the Sustainability and Climate Risk™ certificate and on-going educational opportunities through Continuing Professional Development. Through the GARP Benchmarking Initiative and GARP Risk Institute, GARP sponsors research in risk management and promotes collaboration among practitioners, academics and regulators. Founded in 1996, governed by a Board of Trustees, GARP is headquartered in Jersey City, NJ, with offices in London, Washington, D.C., Beijing, and Hong Kong. Find more information on garp.org or follow GARP on LinkedIn, Facebook, and Twitter.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release

OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly

Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release

Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit

Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release

New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc

LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release

Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital

Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release

This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye